A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed Wegovy for weight loss in a clinical trial sponsored by Eli ... Experts agree that the findings are encouraging, but also stress the ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average ... who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average ... who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.